A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
NCT01561833
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
T Cell Lymphoma
Interventions
DRUG:
Sorafenib
Sponsor
Yale University